China SXT Pharmaceuticals (NASDAQ:SXTC) Issues Quarterly Earnings Results

China SXT Pharmaceuticals (NASDAQ:SXTC) announced its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, reports. The business had revenue of $0.26 million during the quarter.

China SXT Pharmaceuticals Trading Up 16.6%

Shares of SXTC stock traded up $0.35 during trading on Wednesday, hitting $2.46. The company had a trading volume of 47,556 shares, compared to its average volume of 188,488. China SXT Pharmaceuticals has a one year low of $1.25 and a one year high of $1,046.98. The stock’s 50-day moving average price is $1.90 and its 200 day moving average price is $37.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of China SXT Pharmaceuticals during the fourth quarter worth $36,000. Citadel Advisors LLC acquired a new position in China SXT Pharmaceuticals during the 3rd quarter worth about $78,000. Finally, Virtu Financial LLC grew its position in shares of China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after buying an additional 15,013 shares during the last quarter. 5.02% of the stock is currently owned by institutional investors.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.